By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...
A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...
Embattled genetics testing giant 23andMe is thinking of selling itself as it runs out of cash. The company needs ...
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
It is incumbent not only on people to have the willingness to learn, but also on pharmaceutical and scientific industries to ...
Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...
The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...
Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, ...
The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback